Baichuan AI pivots to healthcare, IPO planned for 2027

What the business is

A Chinese AI healthcare company: self-developed healthcare large model Baichuan-M3 (open-sourced) and AI consultation product Baixiaoying (百小应), entering from scenarios such as pediatrics and oncology, providing serious healthcare decision support to patients, and later commercializing through service packages or partnerships with pharmaceutical and medical device companies.

Starting capital：In July 2024, it completed a Series A funding round of RMB 5 billion (during a capital winter); as of January 2026, its book cash reserves were approximately RMB 3 billion.

How it started

In 2023, former Sogou CEO Wang Xiaochuan founded Baichuan AI; the 'Bai' (百) in the company's name means bio (biology). He said he wanted to work on healthcare from day one, but in 2023 'AI healthcare' was not a good story, so the company first positioned itself as a general-purpose model builder aiming to 'create China's OpenAI,' and in July 2024 it secured a RMB 5 billion Series A during the capital winter. In the previous decade, Wang Xiaochuan had invested in Airdoc (鹰瞳科技) and Xiaolu TCM (小鹿中医) as an individual and through Sogou, and had worked on Sogou Mingyi (搜狗明医), but none succeeded.

What happened

Just half a year after the funding round, DeepSeek R1 was released, the general-purpose model story lost its scarcity, and co-founders left one after another; at the mid-year strategy meeting in July 2024, the company decided to go all in on healthcare; in April 2025, Wang Xiaochuan sent an internal memo stating that the 'front lines were stretched too far' and that the company would focus on healthcare; in March 2025, together with Beijing Children's Hospital and others, it released the Futang·Baichuan pediatric large model and proposed building an AI pediatric doctor at the attending-physician level of a Grade III Class A hospital within 3 years; on January 13, 2026, it open-sourced Baichuan-M3, which ranked first on both OpenAI's HealthBench and its Hard subset, with a medical hallucination rate of 3.5, and launched the Baixiaoying AI consultation service.

How it ended up

Still running: as of 2026-09-01, it had about RMB 3 billion on hand and planned to launch an IPO in 2027; M3 has been open-sourced and provides consultations through Baixiaoying, and in 2026 it will release an independent consumer product focused on serious healthcare.

What can be applied

Lower narrative proactively when switching tracks; cash reserves enable strategic resolve; vertical moats are data, trust, regulation.